Trial Search Results

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Dendreon

Stanford Investigator(s):

Intervention(s):

  • Biological: sipuleucel-T

Eligibility


Inclusion Criteria:

   - subjects must be at least 18 years of age

   - subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
   their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to
   enrollment

   - subjects must understand and sign an informed consent form

Exclusion Criteria:

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
6507361252
Not Recruiting